Serum Institute of India to acquire a 50% stake in SCHOTT Kaisha.

Serum Institute of India, an Indian biotechnology and biopharmaceuticals company, agreed to acquire a 50% stake in SCHOTT Kaisha, a anufacturer of pharmaceutical glass packages and containers, from Kairus Dadachanji and Shapoor Mistry. Financial terms were not disclosed. “Even the best medication can’t reach the patient without the right packaging. Securing this supply chain is of strategic importance. SCHOTT is the perfect partner for us to do this because of their expertise and global network. As a longtime customer, we use their vials, ampoules and syringes to store our vaccines including COVISHIELD. Working even closer together is in the best interest of global health," Adar Poonawalla, Serum Institute of India CEO.